冠状动脉支架在稳定和不稳定心痛患者的冠状动脉支架期间使用过器装置进行远距离保护
Annalisa Angelini1, Paolo Rubartelli, Flavio Mistrorigo
1Department of Pathology, University of Padua Medical School, Via A. Gabelli, 61, 35121 Padua, Italy.
Circulation
|July 28, 2004
概括
穿皮冠状动脉干预 (PCI) 期间的过器保护有效捕获栓塞残留物. 不稳定的心痛和年龄较大预测颗粒大小更大,支持高风险患者使用设备.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 生物医学工程 生物医学工程
背景情况:
- 远端栓塞是皮肤穿冠状动脉干预 (PCI) 期间的风险.
- 过器保护装置可用于减轻这种风险.
- 了解栓塞碎片的特征对于优化PCI结果至关重要.
研究的目的:
- 在本地冠状动脉中植入支架时评估微栓塞.
- 为了评估由Angioguard过器捕获的碎片的数量和特征.
- 为了确定血栓颗粒大小的临床和血管学预测因素.
主要方法:
- 39名冠状动脉病变患者接受了带有保护镜的选择性支架.
- 过器收集的碎片进行了大小和特征分析.
- 临床和血管学数据与病理发现相关.
主要成果:
- 在75.6%的过器中存在碎片,颗粒大小在47至2503微米之间.
- 在85.7%的含有碎片的过器中发现了大于300微米的粒子.
- 不稳定的心痛和年龄>67岁是较大的栓塞颗粒大小 (P<0.05) 的独立预测因素.
结论:
- 过器保护装置可以限制PCI期间的栓塞.
- 这些设备在高风险患者中特别有益,包括患有不稳定性胸痛或老年患者.
- 减少栓塞事件可能会改善PCI后患者的治疗结果.
相关概念视频
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...


